Search Results

BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced its development of a novel exosome-based biologic program targeting obesity.

Exosomes show potential to treat myriad conditions, including cancer and inflammation, but experts are divided on whether the therapies are ready for the limelight.

Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases.

Global Exosome Research Market is valued at US$ 172.30 Mn in 2023, and it is expected to reach US$ 570.70 Mn by 2031, with a CAGR of 16.26% during the forecast period of 2024-2031.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that an abstract featuring new preclinical data highlighting the therapeutic potential of its StealthX™ exosome platform technology has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place in Baltimore, Maryland from May 7–11, 2024.

NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”) is pleased to announce that Dr. Lior Shaltiel, CEO and Director at NurExone, was invited to present on “Revolutionizing Spinal Cord Injury Treatment: Harnessing the Potential of Exosomes for Advanced Therapy in Comprehensive Approach” at the Exosomes of Europe conference in London in June, 2024.

RION, a clinical-stage regenerative medicine company at the forefront of exosome therapeutics, announced today the first subject was dosed in the Phase 2 clinical trial with its novel product, known as Purified Exosome Product™ (PEP™).

EverZom, a CNRS/University Paris Cité spin-off specializing in exosomes, unveils its proprietary pipeline of exosome biotherapies developed thanks to its proprietary innovation platform.